Safety and efficacy of esreboxetine in patients with fibromyalgia: A fourteen‐week, randomized, double‐blind, placebo‐controlled, multicenter clinical trial
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Objective: To evaluate the efficacy, tolerability, and safety of multiple fixed dosages of esreboxetine for the treatment of fibromyalgia. Methods: Patients meeting the American College of Rheumatology criteria for fibromyalgia were randomized to receive esreboxetine at dosages of 4 mg/day (n = 277), 8 mg/day (n = 284), or 10 mg/day (n = 283) or matching placebo (n = 278) for 14 weeks. The primary efficacy outcomes were the weekly mean pain score and the Fibromyalgia Impact Questionnaire (FIQ) total score at week 14. Secondary efficacy measures included scores for the Patient's Global Impression of Change (PGIC) scale, the Global Fatigue Index (GFI), and the 36‐item Short‐Form health survey (SF‐36; physical function scale only) at week 14. The safety profile of esreboxetine was evaluated based on adverse events and other safety measures. Results: Patients receiving all dosages of esreboxetine demonstrated statistically significant improvements in the pain score (P ≤ 0.025), the FIQ score (P ≤ 0.023), and the PGIC score (P ≤ 0.007) compared with patients in the placebo group. Additionally, patients receiving esreboxetine at dosages of 4 mg/day and 8 mg/day showed statistically significant improvements in the GFI score compared with those receiving placebo (P = 0.001). No significant differences in SF‐36 physical function scores were observed between patients receiving esreboxetine (any dosage) and those receiving placebo. Adverse events were mostly mild to moderate in severity; insomnia, constipation, dry mouth, nausea, dizziness, hot flush, headache, hyperhidrosis, and palpitations were reported most frequently. Conclusion: Esreboxetine was generally well tolerated and was associated with significant improvements in pain, FIQ, PGIC, and fatigue scores compared with placebo. The lack of a dose‐response relationship in both the efficacy and safety analyses suggests that esreboxetine at a dosage of 4 mg/day would offer clinical benefit with the least risk of drug exposure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Millan, M. J. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00009-6 · Cited by 3,035
Arnold, L. M., Lu, Y., Crofford, L. J., Wohlreich, M., Detke, M. J., Iyengar, S., & Goldstein, D. J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20485 · Cited by 624
Self-citationArnold, L. M., Rosen, A., Pritchett, Y. L., D'Souza, D. N., Goldstein, D. J., Iyengar, S., & Wernicke, J. F. (2005) · Pain · doi:10.1016/j.pain.2005.06.031 · Cited by 471
Self-citationMinimal Clinically Important Difference in the Fibromyalgia Impact Questionnaire
BENNETT, R. M., BUSHMAKIN, A. G., CAPPELLERI, J. C., ZLATEVA, G., & SADOSKY, A. B. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.081090 · Cited by 407
ACCOUNTING FOR DROPOUT BIAS USING MIXED-EFFECTS MODELS
Mallinckrodt, C. H., Clark, W. S., & David, S. R. (2001) · Journal of Biopharmaceutical Statistics · doi:10.1081/bip-100104194 · Cited by 398
Treatment of fibromyalgia with antidepressants: A meta-analysis
O’Malley, P. G., Balden, E., Tomkins, G., Santoro, J., Kroenke, K., & Jackson, J. L. (2000) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2000.06279.x · Cited by 340
Arnold, L. M., Hess, E. V., Hudson, J. I., Welge, J. A., Berno, S. E., & Keck, P. E. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01089-0 · Cited by 261
Self-citationA Double-blind Placebo Controlled Trial of Fluoxetine in Fibromyalgia
Wolfe, F., Cathey, M. A., & Hawley, D. J. (1994) · Scandinavian Journal of Rheumatology · doi:10.3109/03009749409103725 · Cited by 252
Comparative Efficacy and Harms of Duloxetine, Milnacipran, and Pregabalin in Fibromyalgia Syndrome
Häuser, W., Petzke, F., & Sommer, C. (2010) · The Journal of Pain · doi:10.1016/j.jpain.2010.01.002 · Cited by 216
Biology and therapy of fibromyalgia. New therapies in fibromyalgia.
Arnold (2006) · Arthritis Research & Therapy · doi:10.1186/ar1971 · Cited by 145
Cited by
Fibromyalgia: A Clinical Review
Clauw, D. J. (2014) · JAMA · doi:10.1001/jama.2014.3266 · Cited by 1,674
Fibromyalgia and related conditions
Clauw, D. J. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.03.014 · Cited by 259
Beyond pain in fibromyalgia: Insights into the symptom of fatigue
Vincent, A., Benzo, R. P., Whipple, M. O., McAllister, S. J., Erwin, P. J., & Saligan, L. N. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4395 · Cited by 133
“Esreboxetine 2 double-blind, placebo-controlled, multicenter RCTs (n = 1,389) [125,126] MAF No clinically meaningful improvement”
BackgroundCurrent and Emerging Pharmacotherapy for Fibromyalgia
Tzadok, R., & Ablin, J. N. (2020) · Pain Research and Management · doi:10.1155/2020/6541798 · Cited by 122
“Selective noradrenaline reuptake inhibitors (NRIs), such as reboxetine and its enantiomer esreboxetine, were also suggested as possible treatments for FMS, while the body of evidence regarding the efficacy of reboxetine is rather sporadic and is based mostly on case reports [13], esreboxetine was shown to reduce pain,…”
Background
Metadata
- Authors
- Arnold, L. M., Hirsch, I., Sanders, P., Ellis, A., & Hughes, B.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2012-06-26
- Volume
- 64
- Issue
- 7
- Pages
- 2387-2397
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2019759444
- Cited by
- 40
- References
- 10
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and efficacy of esreboxetine in patients with fibromyalgia: A fourteen‐week, randomized, double‐blind, placebo‐controlled, multicenter clinical trial. https://app.cochat.ai/papers/10.1002/art.34390
- The paper
- Arnold, L. M., Hirsch, I., Sanders, P., Ellis, A., & Hughes, B. (2012). Safety and efficacy of esreboxetine in patients with fibromyalgia: A fourteen‐week, randomized, double‐blind, placebo‐controlled, multicenter clinical trial. Arthritis & Rheumatism. https://doi.org/10.1002/art.34390
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.